Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Utah Medical ProductsFRA:UTM -2.50%73 3-Year ROIIC % is 75.60 as of Dec. 2025, which is 1009% above its 10-year median of 6.82. GuruFocus rates FRA:UTM with a GF Score™ of 73/100 and a GF Value™ of €49.20. The stock has 8 warning signs investors should review. Among 793 Medical Devices & Instruments companies, Utah Medical Products ranks better than 85.88% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Utah Medical Products's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 75.60%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Utah Medical Products's 3-Year ROIIC % or its related term are showing as below:
FRA:UTM's 3-Year ROIIC % is ranked better than 85.88% of 793
companies
in the Medical Devices & Instruments industry
Industry Median: 1.57
vs FRA:UTM: 75.60
Utah Medical Products (FRA:UTM) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Utah Medical Products 3-Year ROIIC % Related Terms
Utah Medical Products 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Utah Medical Products's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:UTM vs EMBC, SMTI, PDEX: 3-Year ROIIC % Comparison
For the Medical Instruments & Supplies subindustry, Utah Medical Products's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Utah Medical Products 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Utah Medical Products's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Utah Medical Products's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Utah Medical Products (FRA:UTM) has a 3-Year ROIIC % of 75.60 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Utah Medical Products and its competitors. This is 1009% above median its historical median of 6.82. According to the industry distribution chart, Utah Medical Products ranks #112 out of 793 companies in the Medical Devices & Instruments industry, placing it in the top 14.1%.
Is Utah Medical Products' 3-Year ROIIC % too high?
Utah Medical Products' current 3-Year ROIIC % of 75.60 is 1009% above median its 10-year median of 6.82. The Medical Devices & Instruments industry median 3-Year ROIIC % is 1.57. Utah Medical Products' value of 75.60 is 4715.3% above this industry median. Based on the distribution chart, Utah Medical Products ranks #112 out of 793 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Utah Medical Products has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Utah Medical Products' 3-Year ROIIC % compare to EMBC and SMTI?
According to the Medical Devices & Instruments industry distribution chart, Utah Medical Products ranks #112 out of 793 companies for 3-Year ROIIC %. This places Utah Medical Products in the top 14% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 1.57. Utah Medical Products' value of 75.60 is 4715.3% above this benchmark. While the company's 10-year median is 6.82 vs. the industry median of 1.57, Utah Medical Products has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.57, based on 793 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Utah Medical Products's current 3-Year ROIIC % of 75.60 is 4715.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Utah Medical Products and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Utah Medical Products's current 3-Year ROIIC % is 75.60, which is 1009% above median its own 10-year median of 6.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Utah Medical Products stock overvalued right now?
Utah Medical Products (FRA:UTM) has a current 3-Year ROIIC % of 75.60. The stock's GF Value™ is €49.20, compared to a current price of €58.50 — trading 18.9% above its estimated fair value. The current 3-Year ROIIC % is 75.60, which is 1009% above median its 10-year median of 6.82 and 4715.3% above the Medical Devices & Instruments industry median of 1.57. Utah Medical Products' overall GF Score™ is 73/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Utah Medical Products (FRA:UTM), the current 3-Year ROIIC % is 75.60 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Utah Medical Products (FRA:UTM) Overvalued in 2026?
Based on GuruFocus' analysis, Utah Medical Products stock appears to be overvalued.
The current stock price of €58.50 is trading 18.9% above its estimated GF Value™ of €49.20.
Key valuation signals for FRA:UTM:
3-Year ROIIC %: 75.60 (1009% above median its 10-year median of 6.82)
GF Value™: €49.20 vs. price of €58.50 (18.9% above fair value)
Industry Position: 4715.3% above the Medical Devices & Instruments median (#112 of 793)
No single metric tells the full story. See the FRA:UTM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable, and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, and Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals, and outpatient clinics and physicians' offices.
73GF Score
Get the complete analysis for FRA:UTM
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:UTM has been successfully added to your 
